Bryan, Garnier & Co acts as Sole Financial Advisor to Selfapy, one of the leading providers in digital therapeutics for mental health disorders in Germany, on its growth financing from strategic investor Medice Arzneimittel and existing shareholders

Selfapy is one of Germany's leading providers of online support for mental health disorders and was founded in 2016 by the two psychologists Nora Blum and Katrin Bermbach.

In Germany alone, around 18 million people suffer from a mental illness such as burnout, depression or anxiety disorders and patients often have to wait up to six months for treatment. Selfapy offers clinically-proven courses that effectively support patients without any waiting times. Moreover, as certified digital health applications (DiGA), Selfapy’s courses are fully reimbursed by all statutory health insurers, covering c.90% of patients.

Fuelled by increasing adoption, the company has seen a strong uptake in demand for its courses. This funding round will enable Selfapy to continue its strong growth trajectory and support the development of further digital health applications to strengthen its market-leading position.

Bryan, Garnier & Co acts as Sole Financial Advisor to Selfapy, one of the market leaders in digital therapeutics for mental health disorders in Germany, successfully completing an equity capital raise with leading strategic and institutional investors.

The round was led by Medice Arzneimittel, a family-owned pharmaceutical company focused on the treatment of ADHD. All existing shareholders co-invested, including the medtech investor SHS, Think.Health Ventures, IBB Ventures and HTGF.

Bryan, Garnier & Co worked closely with the management and shareholders to evaluate various strategic options to support Selfapy’s growth and consolidate its market-leading position as digital therapeutics provider focused on mental health disorders. Bryan, Garnier & Co led a competitive process involving all relevant strategic and financial sponsors within the digital health space across Europe, the US and Asia.

This marks another landmark transaction for Bryan, Garnier & Co’s healthcare practice and further demonstrates its expertise in leading growth financing rounds within the digital health space.

"Bryan Garnier’s conviction of Selfapy’s potential was instrumental in attracting the right investors who would share our vision. The team at Bryan Garnier supported us in each step of this transaction in a well-managed process, leveraging their reach to produce an ideal outcome for all parties."

— Nora Blum – Founder & Co-CEO of Selfapy

"Bryan Garnier’s know-how was extremely valuable in positioning the equity story and framing the transaction to help run a competitive process. Bryan Garnier’s deep network of international strategic and financial investors ensured that we found the ideal partner to take Selfapy to the next level"

— Dr. Cornelius Maas, Partner at SHS Capital

Founded in 2016, Selfapy is one of Germany’s leading providers of digital therapeutics for mental health conditions such as depression, anxiety or eating disorders. Selfapy’s online courses, which are based on the methods of cognitive behavioural therapy, significantly reduce symptoms for people suffering from mental health disorders, as proven by a number of randomised controlled trials. As certified digital health applications (DiGA), Selfapy’s online courses are fully reimbursed by all statutory health insurers in Germany and therefore free for patients, thus significantly lowering the barriers to psychological treatment for everyone in need.